Pharma Focus Asia

Oncodesign Concludes a Long Term Service-Based Partnership with ERYTECH in Oncology

Wednesday, March 28, 2018

Oncodesign, a biopharma company specialized in precision medicine with the mission of discovering new therapeutic molecules to fight cancer and other serious illnesses with no known effective treatment, is announcing that it has concluded a service-based partnership agreement in oncology with ERYTECH Pharma.

Philippe Genne, Oncodesign’s CEO and founder, said: “We are delighted to be working together with ERYTECH, one of the most innovative biotech companies, in the fight against rare forms of cancer and orphan diseases. This latest long-term agreement is a testament to the appeal of the new service offering we launched recently. By harnessing our expertise in the discovery of innovative therapies, we are able to support our customers across a broad range of services requiring the full breadth of our scientific teams’ expertise and ingenuity to select and guide the best drug candidates. We are excited to be supporting ERYTECH over the long term with the preclinical development phase of its programs and in the most promising areas.”

ERYTECH has selected Oncodesign as a key partner for conducting the preclinical trials of the drug candidates developed on its Erycaps platform, including eryaspase and erymethionase. Eryaspase, also known as Graspa®, its marketing name, consists of an enzyme, L-asparaginase, encapsulated inside red blood cells. Eryaspase has already demonstrated positive efficacy and safety results in different studies, including Phase III trials in acute lymphoblastic leukemia (ALL) and Phase II trials in metastatic pancreatic cancer.

This two-year preclinical experimentation partnership fits perfectly with Oncodesign’s strategy of increasing its share of the services market1 and boosting the average unit size of its contracts. The collaboration also includes Oncodesign’s scientific and technological support for ERYTECH’s oncology research.

Oncodesign has been working for over 20 years on the preclinical evaluation of anti-cancer therapies. It now possesses a set of innovative technology platforms such as predictive models for human cancer, the use of medical imaging capacities to accurately measure the treatment effect, and a secure GLP-approved and AAALAC-certified environment for conducting tests involving innovative therapies and for developing companion biomarkers. Oncodesign brings to its partnership with ERYTECH this unique integration of technologies and expertise in a single platform predicated on its know-how in conducting research programs on behalf of leading pharma groups.

The financial terms of the agreement have not been disclosed.

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference